The New England Comparative Effectiveness Public Advisory Council (New England CEPAC) is a nationally-recognized independent appraisal committee. The New England CEPAC convenes three times each year at public meetings to review objective evidence reports and develop recommendations for how stakeholders can apply evidence to improve the quality and value of health care. 

New England CEPAC directly engages clinicians, patients, and payers during public meetings to discuss implications of the evidence for clinical decision-making and coverage policies. Application of evidence takes shape through new medical policies, benefit designs, and patient and clinician tools to improve clinical care and patient outcomes. All members of the New England CEPAC must meet ICER’s criteria for Conflict of Interest.

 
 
 

Next New England CEPAC Meeting

Main Review
January 20, 2023

New England CEPAC

The New England CEPAC’s 2023 public meeting on treatments for multiple sclerosis:

Interventions of Interest:

Monoclonal Antibodies

    • natalizumab (Tysabri®, Biogen)

    • ofatumumab (Kesimpta®, Novartis)

    • ocrelizumab (Ocrevus®, Genentech)

    • rituximab (Rituxan®, Genentech, and biosimilars)

    • ublituximab (Briumvi™, TG Therapeutics)

Oral Therapies

    • dimethyl fumarate (Tecfidera®, Biogen, and generics)

    • diroximel fumarate (Vumerity®, Biogen)

    • monomethyl fumarate (Bafiertam®, Banner Life Sciences)

    • fingolimod (Gilenya®, Novartis)

    • ozanimod (Zeposia®, Bristol Myers Squibb)

    • ponesimod (Ponvory®, Janssen)

    • siponimod (Mayzent®, Novartis)

    • teriflunomide (Aubagio®, Sanofi)

Multiple Sclerosis: CIS, RRMS, and SPMS Meeting Agenda

New England CEPAC Members

Jason H. Wasfy, MD, MPhil

New England CEPAC Chair; Massachusetts General Hospital Heart Center

Robert H. Aseltine, Jr., PhD

UCONN Health

Rena Conti, PhD

Boston University

Austin Frakt, PhD

VA Boston Healthcare System

Marthe Gold, MD, MPH

CUNY School of Medicine

Megan Golden, JD

Mission:Cure

George Goshua, MD, MSc

Assistant Professor of Medicine (Hematology)

Claudio W. Gualtieri, JD

Health and Human Services, Office of Policy Management (OPM)

Rebecca Kirch, JD

Health Care Quality and Value for the NPAF

Stephen Kogut, PhD, MBA RPh

University of Rhode Island College of Pharmacy

Donald Kreis, JD

New Hampshire Office of the Consumer Advocate

Tara Lavelle, PhD

Center for the Evaluation of Value and Risk in Health at Tufts Medical Center

Kimberly Lenz, PharmD (ex-officio)

University of Massachusetts Medical School Commonwealth Medicine Division

Greg Low, RPh, PhD

MGPO Pharmacy Quality and Utilization Program

Aaron Mitchell, MD, MPH

Memorial Sloan Kettering Cancer Center

Stephanie Nichols, PharmD, BCPS, BCPP, FCCP

University of New England College of Pharmacy

Brian P. O’Sullivan, MD

Geisel School of Medicine, Dartmouth College

Leslie Ochs, PharmD, PhD, MSPH

University of New England College of Pharmacy

Jeanne Ryer, MS

NH Citizens Health Initiative

Jason L. Schwartz, PhD

Department of Health Policy and Management, Yale School of Public Health